Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name ANRIL
   Synonyms CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS
   Region GRCh38_9:21994778-22121097    Sequence
   Ensembl ENSG00000240498
   RefSeq NR_003529
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name hepatocellular carcinoma
   ICD-0-3 C22.0  M8170/3
   Methods qRT-PCR, Luciferase reporter assay, in vitro knockdown, RIP
   Sample HCC tissue, HCC cell lines (SMMC772, HUH7, Hep3B, and HepG2)
   Expression Pattern up-regulated
   Function Description

ANRIL was upregulated and miR-122-5p was downregulated in HCC tissues and cells. ANRIL was negatively correlated with miR-122-5p expression in HCC tissues. Knockdown of ANRIL or miR-122-5p overexpression suppressed HCC cell viability, colony formation ability, metastasis, and invasion. ANRIL was demonstrated to directly bind to miR-122-5p and inhibit its expression.Forced expression of ANRIL abolished the inhibitory effect of miR-122-5p overexpression on HCC progression. In vivo experiment demonstrated that ANRIL knockdown impeded tumor growth in vivo and increased miR-122-5p expression.

   Pubmed ID 29127494
   Year 2017
   Title Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma.
   External Links
   Links for  ANRIL GenBank       HGNC       lncrnadb       Noncode
   Links for  hepatocellular carcinoma Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.